Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Cannabinoid Receptor CB1 Inverse Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cannabinoid Receptor CB1 Inverse Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cannabinoid Receptor CB1 Inverse Agonists: Overview
The cannabinoid receptor 1 (CB1) is the most abundantly expressed G protein-coupled receptor (GPCR) in the brain. CB1 elicits its physiological responses by coupling primarily to Gi/o proteins to inhibit adenylate cyclase and cyclic AMP signaling.
Function – CB1R is encoded by the gene CNR1 and consists of 472 amino acids in humans (473 amino acids in rat and mouse, with 97–99% amino acid sequence identity among these species). The full-length CB1R dominates in the brain and skeletal muscle, whereas the CB1Rb (with 33 amino acid deletion at the N-terminus) shows a higher expression level in the liver and pancreatic islet cells where it is involved in metabolism.The CB1 receptor is a pre-synaptic heteroreceptor that modulates neurotransmitter release when activated in a dose-dependent, stereoselective and pertussis toxin-sensitive manner.The CB1 receptor is activated by cannabinoids, generated naturally inside the body (endocannabinoids) or introduced into the body as cannabis or a related synthetic compound.
Cannabinoid Receptor CB1 Inverse Agonists- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Cannabinoid Receptor CB1 Inverse Agonists which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders. These types of molecules inhibit the signal induced by the CB1 receptor, and even reverse its biological response (e.g.: no signal to seek food, signal to increase energy expenditure and speed up metabolism at rest, no fibrogenesis or even reverse fibrogenesis).
Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs Chapters
This segment of the Cannabinoid Receptor CB1 Inverse Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs
Further product details are provided in the report……..
Cannabinoid Receptor CB1 Inverse Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Cannabinoid Receptor CB1 Inverse Agonists drugs segregated based on following parameters that define the scope of the report, such as:
Cannabinoid Receptor CB1 Inverse Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Receptor CB1 Inverse Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Receptor CB1 Inverse Agonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Cannabinoid Receptor CB1 Inverse Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cannabinoid Receptor CB1 Inverse Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cannabinoid Receptor CB1 Inverse Agonists: Overview
The cannabinoid receptor 1 (CB1) is the most abundantly expressed G protein-coupled receptor (GPCR) in the brain. CB1 elicits its physiological responses by coupling primarily to Gi/o proteins to inhibit adenylate cyclase and cyclic AMP signaling.
Function – CB1R is encoded by the gene CNR1 and consists of 472 amino acids in humans (473 amino acids in rat and mouse, with 97–99% amino acid sequence identity among these species). The full-length CB1R dominates in the brain and skeletal muscle, whereas the CB1Rb (with 33 amino acid deletion at the N-terminus) shows a higher expression level in the liver and pancreatic islet cells where it is involved in metabolism.The CB1 receptor is a pre-synaptic heteroreceptor that modulates neurotransmitter release when activated in a dose-dependent, stereoselective and pertussis toxin-sensitive manner.The CB1 receptor is activated by cannabinoids, generated naturally inside the body (endocannabinoids) or introduced into the body as cannabis or a related synthetic compound.
Cannabinoid Receptor CB1 Inverse Agonists- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Cannabinoid Receptor CB1 Inverse Agonists which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders. These types of molecules inhibit the signal induced by the CB1 receptor, and even reverse its biological response (e.g.: no signal to seek food, signal to increase energy expenditure and speed up metabolism at rest, no fibrogenesis or even reverse fibrogenesis).
Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs Chapters
This segment of the Cannabinoid Receptor CB1 Inverse Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs
- Cannabidiol: Stero Biotechs
- INV-101: Inversago Pharma
Further product details are provided in the report……..
Cannabinoid Receptor CB1 Inverse Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Cannabinoid Receptor CB1 Inverse Agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cannabinoid Receptor CB1 Inverse Agonists
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cannabinoid Receptor CB1 Inverse Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Receptor CB1 Inverse Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Receptor CB1 Inverse Agonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cannabinoid Receptor CB1 Inverse Agonists R&D.
- The therapies under development are focused on novel approaches for Cannabinoid Receptor CB1 Inverse Agonists.
- Cannabinoid Receptor CB1 Inverse Agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cannabinoid Receptor CB1 Inverse Agonists drugs?
- How many Cannabinoid Receptor CB1 Inverse Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Cannabinoid Receptor CB1 Inverse Agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cannabinoid Receptor CB1 Inverse Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cannabinoid Receptor CB1 Inverse Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Cannabinoid Receptor CB1 Inverse Agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cannabinoid Receptor CB1 Inverse Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cannabinoid Receptor CB1 Inverse Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cannabinoid Receptor CB1 Inverse Agonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Cannabidiol: Stero Biotechs
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
INV-101: Inversago Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cannabinoid Receptor CB1 Inverse Agonists Key Companies
Cannabinoid Receptor CB1 Inverse Agonists Key Products
Cannabinoid Receptor CB1 Inverse Agonists- Unmet Needs
Cannabinoid Receptor CB1 Inverse Agonists- Market Drivers and Barriers
Cannabinoid Receptor CB1 Inverse Agonists- Future Perspectives and Conclusion
Cannabinoid Receptor CB1 Inverse Agonists Analyst Views
Cannabinoid Receptor CB1 Inverse Agonists Key Companies
Appendix
Executive Summary
Cannabinoid Receptor CB1 Inverse Agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cannabinoid Receptor CB1 Inverse Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cannabinoid Receptor CB1 Inverse Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cannabinoid Receptor CB1 Inverse Agonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Cannabidiol: Stero Biotechs
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
INV-101: Inversago Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cannabinoid Receptor CB1 Inverse Agonists Key Companies
Cannabinoid Receptor CB1 Inverse Agonists Key Products
Cannabinoid Receptor CB1 Inverse Agonists- Unmet Needs
Cannabinoid Receptor CB1 Inverse Agonists- Market Drivers and Barriers
Cannabinoid Receptor CB1 Inverse Agonists- Future Perspectives and Conclusion
Cannabinoid Receptor CB1 Inverse Agonists Analyst Views
Cannabinoid Receptor CB1 Inverse Agonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cannabinoid Receptor CB1 Inverse Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cannabinoid Receptor CB1 Inverse Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cannabinoid Receptor CB1 Inverse Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cannabinoid Receptor CB1 Inverse Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
